Nakagawa R, Onishi Y, Kawajiri A, Onodera K, Furukawa E, Sano S, Saito K, Ichikawa S, Fujiwara T, Fukuhara N, Harigae H. Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma. Ann Hematol. 2019 Aug;98(8):1999-2001. doi: 10.1007/s00277-019-03645-7.
Mutoh T, Ishii T, Shirai T, Akita K, Kamogawa Y, Fujita Y, Sato H, Shirota Y, Fujii H, Harigae H. Refractory Takayasu arteritis successfully treated withrituximab: case-based review. Rheumatol Int. 2019 Aug 6. doi:10.1007/s00296-019-04390-w. 4: Mutoh T, Shirai T, Fujii H, Ishii T, Harigae H. Insufficient use of corticosteroids without immunosuppressants results in higher relapse in Takayasu arteritis. J Rheumatol. 2019 May 15. pii: jrheum.181219. doi:10.3899/jrheum.181219.
Shirai T, Shirota Y, Fujii H, Ishii T, Harigae H. Four distinct clinical phenotypes of vasculitis affecting medium-sized arteries. Scand J Rheumatol. 2019 Jul;48(4):308-314. doi: 10.1080/03009742.2018.1551965.
Saito K, Fujiwara T, Hatta S, Morita M, Ono K, Suzuki C, Fukuhara N, Onishi Y, Nakamura Y, Kawamata S, Shimizu R, Yamamoto M, Harigae H. Generation and Molecular Characterization of Human Ring Sideroblasts: a Key Role of Ferrous Iron in Terminal Erythroid Differentiation and Ring Sideroblast Formation. Mol Cell Biol. 2019 Mar 19;39(7). pii: e00387-18. doi: 10.1128/MCB.00387-18.
Ochi T, Onishi Y, Nasu K, Onodera K, Kobayashi M, Ichikawa S, Fujiwara T, Fukuhara N, Yamada-Fujiwara M, Harigae H. Umbilical Cord Blood Transplantation Using Reduced-Intensity Conditioning without Antithymocyte Globulin in Adult Patients with Severe Aplastic Anemia. Biol Blood Marrow Transplant. 2019 Feb;25(2):e55-e59. doi: 10.1016/j.bbmt.2018.09.039.
Fujiwara T, Harigae H. Molecular pathophysiology and genetic mutations in congenital sideroblastic anemia. Free Radic Biol Med. 2019 Mar;133:179-185. doi:10.1016/j.freeradbiomed.2018.08.008.
Harigae H, Hino K, Toyokuni S. Iron as Soul of Life on Earth Revisited: From Chemical Reaction, Ferroptosis to Therapeutics. Free Radic Biol Med. 2019 Mar;133:1-2. doi: 10.1016/j.freeradbiomed.2019.01.042.
Yokoyama H, Kanda J, Kato S, Kondo E, Maeda Y, Saji H, Takahashi S, Onizuka M, Onishi Y, Ozawa Y, Kanamori H, Ishikawa J, Ohno Y, Ichinohe T, Takanashi M, Kato K, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Effects of HLA mismatch on cytomegalovirus reactivation in cord blood transplantation. Bone Marrow Transplant. 2019 Jul;54(7):1004-1012. doi: 10.1038/s41409-018-0369-0. PMID: 30401965
Fukuhara N, Ishizawa K. Current approaches and future perspectives for advanced-stage follicular lymphoma with a low tumor burden. Jpn J Clin Oncol. 2019 Apr 1;49(4):306-310. doi: 10.1093/jjco/hyz008. PMID: 30715424.
Takahashi T, Ichikawa S, Harigae H. Successful cord blood transplantation for a paroxysmal nocturnal hemoglobinuria complicated with Budd-Chiari syndrome and myelodysplastic syndrome. Ann Hematol. 2019 Aug 9. doi:10.1007/s00277-019-03781-0.
Fujishima F, Katsushima H, Fukuhara N, Konosu-Fukaya S, Nakamura Y, Usubuchi H, Sato S, Ota Y, Yashima-Abo A, Nakamura T, Nakaya N, Harigae H, Sasano H, Ichinohasama R. Immunohistochemical pattern of c-MYC protein judged as "+/(weak)+/-" by a new notation correlates with MYC gene nontranslocation in large B-cell lymphoma. Hum Pathol. 2019 Mar;85:112-118. doi:10.1016/j.humpath.2018.10.025.
Iwaki K, Fujiwara T, Ito T, Suzuki C, Sasaki K, Ono K, Saito K, Fukuhara N, Onishi Y, Yokoyama H, Fujimaki S, Tanaka T, Tamura H, Fujiwara M, Harigae H. Flow Cytometry-Based Photodynamic Diagnosis with 5-Aminolevulinic Acid for the Detection of Minimal Residual Disease in Multiple Myeloma. Tohoku J Exp Med. 2019 Sep;249(1):19-28. doi: 10.1620/tjem.249.19. PMID: 31511451.
Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, Egyed M, Ichikawa S, Ito Y, Kim JS, Ninomiya H, Schrezenmeier H, Sica S, Usuki K, Sicre de Fontbrune F, Soret J, Sostelly A, Higginson J, Dieckmann A, Gentile B, Anzures-Cabrera J, Shinomiya K, Jordan G, Biedzka-Sarek M, Klughammer B, Jahreis A, Bucher C, Peffault de Latour R. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood. 2020 Mar 19;135(12):912-920. doi: 10.1182/blood.2019003399. PMID: 31978221; PMCID: PMC7082616.
Kondo H, Watanabe R, Okazaki S, Kuriyama K, Harigae H, Fujii H. Coexistence of rheumatoid arthritis and systemic lupus erythematosus is still rare in the biologic era: Report of seven cases and literature review. Mod Rheumatol. 2019 Oct 30:1-2. doi: 10.1080/14397595.2019.1682795. Epub ahead of print. PMID: 31625433.
Akaishi T, Yasaka K, Abe M, Fujii H, Watanabe M, Shirai T, Ishizawa K, Takayama S, Kagaya Y, Harigae H, Ishii T. Protein-losing gastroenteropathy with severe hypoalbuminemia associated with Sjögren's syndrome: A case report and review of the literature. J Gen Fam Med. 2019 Oct 16;21(1):24-28. doi: 10.1002/jgf2.281. PMID: 31911886; PMCID: PMC6942935.
Kedar PS, Harigae H, Ito E, Muramatsu H, Kojima S, Okuno Y, Fujiwara T, Dongerdiye R, Warang PP, Madkaikar MR. Study of pathophysiology and molecular characterization of congenital anemia in India using targeted next-generation sequencing approach. Int J Hematol. 2019 Aug 10. doi: 10.1007/s12185-019-02716-9.
Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators. Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. Int J Hematol. 2019 Apr;109(4):426-439. doi:10.1007/s12185-019-02613-1.
Nakamura N, Izumi R, Hoshi Y, Takai Y, Ono R, Suzuki N, Nagai T, Ishii Y, Ishii T, Harigae H, Okada S, Aiba S, Okiyama N, Fujimoto M, Kuroda H, Tateyama M, Aoki M. FDG-PET detects extensive calcinosis cutis in anti-NXP2 antibody-positive dermatomyositis. Rheumatology (Oxford). 2019 Mar 16. pii: kez083. doi:10.1093/rheumatology/kez083.
Fukuhara N, Yamamoto G, Tsujimura H, Chou T, Shibayama H, Yanai T, Shibuya K, Izutsu K. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study. Leuk Lymphoma. 2020 Jan;61(1):176-180. doi: 10.1080/10428194.2019.1654100. Epub 2019 Aug 22. PMID: 31437057.
Maruyama D, Nagai H, Fukuhara N, Kitano T, Ishikawa T, Nishikawa T. Final analysis of a phase II study of ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma. J Clin Exp Hematop. 2019;59(2):98-100. doi: 10.3960/jslrt.19006. PMID: 31257351; PMCID: PMC6661957.
Munakata W, Ando K, Hatake K, Fukuhara N, Kinoshita T, Fukuhara S, Shirasugi Y, Yokoyama M, Ichikawa S, Ohmachi K, Gion N, Aoi A, Tobinai K. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer Sci. 2019 May;110(5):1686-1694. doi: 10.1111/cas.13983. Epub 2019 Mar 28. PMID: 30815927; PMCID: PMC6500982.
Tobinai K, Uchida T, Fukuhara N, Nishikawa T. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study. Int J Hematol. 2019 Mar;109(3):366-368. doi: 10.1007/s12185-018-02577-8. Epub 2019 Jan 8. PMID: 30623356.
Konuma T, Shimomura Y, Ozawa Y, Ueda Y, Uchida N, Onizuka M, Akiyama M, Mori T, Nakamae H, Ohno Y, Shiratori S, Onishi Y, Kanda Y, Fukuda T, Atsuta Y, Ishiyama K; Adult Myelodysplastic Syndrome Working Group of the Japan Society for Hematopoietic Cell Transplantation. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis. Hematol Oncol. 2019 Feb;37(1):85-95. doi: 10.1002/hon.2566. Epub 2018 Nov 19. PMID: 30370627.
Kurosawa S, Yamaguchi T, Oshima K, Yanagisawa A, Fukuda T, Kanamori H, Mori T, Takahashi S, Kondo T, Fujisawa S, Onishi Y, Yano S, Onizuka M, Kanda Y, Mizuno I, Taniguchi S, Yamashita T, Inamoto Y, Okamoto S, Atsuta Y. Employment status was highly associated with quality of life after allogeneic hematopoietic cell transplantation, and the association may differ according to patient age and graft-versus-host disease status: analysis of a nationwide QOL survey. Bone Marrow Transplant. 2019 Apr;54(4):611-615. doi: 10.1038/s41409-018-0343-x. Epub 2018 Oct 4. PMID: 30287939.
Yakushijin K, Ikezoe T, Ohwada C, Kudo K, Okamura H, Goto H, Yabe H, Yasumoto A, Kuwabara H, Fujii S, Kagawa K, Ogata M, Onishi Y, Kohno A, Watamoto K, Uoshima N, Nakamura D, Ota S, Ueda Y, Oyake T, Koike K, Mizuno I, Iida H, Katayama Y, Ago H, Kato K, Okamura A, Kikuta A, Fukuda T. Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019 May;54(5):674-680. doi: 10.1038/s41409-018-0304-4. Epub 2018 Aug 20. PMID: 30127466.